 TG Therapeutics Incs NASDAQ: TGTX shares are plunging after new data showed that ublituximab Ukoniq showed an elevated risk of death in the phase 3 Unity combo trial for chronic lymphocytic leukemia CLL and small lymphocytic lymphoma SLL HC Wainwright has slashed the. 